These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 36404264)

  • 1. Smoking history and pulmonary arterial hypertension: Demographics, onset, and outcomes.
    Frost AE; Zhao C; Farber HW; Benza R; Yen J; Selej M; Elliott CG
    J Heart Lung Transplant; 2023 Mar; 42(3):377-389. PubMed ID: 36404264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries.
    Frost AE; Badesch DB; Barst RJ; Benza RL; Elliott CG; Farber HW; Krichman A; Liou TG; Raskob GE; Wason P; Feldkircher K; Turner M; McGoon MD
    Chest; 2011 Jan; 139(1):128-37. PubMed ID: 20558556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of first-time hospitalizations in patients with newly diagnosed pulmonary arterial hypertension in the REVEAL registry.
    Burger CD; Long PK; Shah MR; McGoon MD; Miller DP; Romero AJ; Benton WW; Safford RE
    Chest; 2014 Nov; 146(5):1263-1273. PubMed ID: 24901386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry.
    Chung L; Domsic RT; Lingala B; Alkassab F; Bolster M; Csuka ME; Derk C; Fischer A; Frech T; Furst DE; Gomberg-Maitland M; Hinchcliff M; Hsu V; Hummers LK; Khanna D; Medsger TA; Molitor JA; Preston IR; Schiopu E; Shapiro L; Silver R; Simms R; Varga J; Gordon JK; Steen VD
    Arthritis Care Res (Hoboken); 2014 Mar; 66(3):489-95. PubMed ID: 23983198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hispanic Ethnicity and Social Determinants of Health in Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry.
    Bernardo RJ; Lu D; Ramirez RL; Hedlin H; Kawut SM; Bull T; De Marco T; Ford HJ; Grinnan D; Klinger JR; McConnell JW; Berman-Rosenzweig E; Shlobin OA; Zamanian RT; de Jesus Perez VA
    Ann Am Thorac Soc; 2022 Sep; 19(9):1459-1468. PubMed ID: 35239467
    [No Abstract]   [Full Text] [Related]  

  • 6. Epidemiology and long-term survival of pulmonary arterial hypertension in the Czech Republic: a retrospective analysis of a nationwide registry.
    Jansa P; Jarkovsky J; Al-Hiti H; Popelova J; Ambroz D; Zatocil T; Votavova R; Polacek P; Maresova J; Aschermann M; Brabec P; Dusek L; Linhart A
    BMC Pulm Med; 2014 Mar; 14():45. PubMed ID: 24629043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry.
    Benza RL; Miller DP; Barst RJ; Badesch DB; Frost AE; McGoon MD
    Chest; 2012 Aug; 142(2):448-456. PubMed ID: 22281797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Portopulmonary hypertension: a report from the US-based REVEAL Registry.
    Krowka MJ; Miller DP; Barst RJ; Taichman D; Dweik RA; Badesch DB; McGoon MD
    Chest; 2012 Apr; 141(4):906-915. PubMed ID: 21778257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Risk factors for death and the clinical features of different subtypes of patients with pulmonary arterial hypertension related to congenital heart disease].
    Xu ZY; Li QQ; Zhang C; Zhang HS; Gu H
    Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Apr; 48(4):315-322. PubMed ID: 32370483
    [No Abstract]   [Full Text] [Related]  

  • 10. Five-Year outcomes of patients enrolled in the REVEAL Registry.
    Farber HW; Miller DP; Poms AD; Badesch DB; Frost AE; Muros-Le Rouzic E; Romero AJ; Benton WW; Elliott CG; McGoon MD; Benza RL
    Chest; 2015 Oct; 148(4):1043-54. PubMed ID: 26066077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL Registry.
    Brown LM; Chen H; Halpern S; Taichman D; McGoon MD; Farber HW; Frost AE; Liou TG; Turner M; Feldkircher K; Miller DP; Elliott CG
    Chest; 2011 Jul; 140(1):19-26. PubMed ID: 21393391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional class improvement and 3-year survival outcomes in patients with pulmonary arterial hypertension in the REVEAL Registry.
    Barst RJ; Chung L; Zamanian RT; Turner M; McGoon MD
    Chest; 2013 Jul; 144(1):160-168. PubMed ID: 23429998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management.
    Barst RJ; McGoon MD; Elliott CG; Foreman AJ; Miller DP; Ivy DD
    Circulation; 2012 Jan; 125(1):113-22. PubMed ID: 22086881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticoagulation in pulmonary arterial hypertension - association with mortality, healthcare utilization, and quality of life: The Pulmonary Hypertension Association Registry (PHAR).
    Garry JD; Kolaitis NA; Kronmal R; Thenappan T; Hemnes A; Grinnan D; Bull T; Chakinala MM; Horn E; Simon MA; De Marco T;
    J Heart Lung Transplant; 2022 Dec; 41(12):1808-1818. PubMed ID: 36150996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL).
    Benza RL; Miller DP; Gomberg-Maitland M; Frantz RP; Foreman AJ; Coffey CS; Frost A; Barst RJ; Badesch DB; Elliott CG; Liou TG; McGoon MD
    Circulation; 2010 Jul; 122(2):164-72. PubMed ID: 20585012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Differences and Outcomes between Methamphetamine-associated and Idiopathic Pulmonary Arterial Hypertension in the Pulmonary Hypertension Association Registry.
    Kolaitis NA; Zamanian RT; de Jesus Perez VA; Badesch DB; Benza RL; Burger CD; Chakinala MM; Elwing JM; Feldman J; Lammi MR; Mathai SC; McConnell JW; Presberg KW; Robinson JC; Sager J; Shlobin OA; Simon MA; Kawut SM; Glidden DV; Singer JP; De Marco T;
    Ann Am Thorac Soc; 2021 Apr; 18(4):613-622. PubMed ID: 33064950
    [No Abstract]   [Full Text] [Related]  

  • 17. Do Patients With Low-Risk Pulmonary Arterial Hypertension Really Benefit From Upfront Combination Therapy?: Insight From the AMBITION Trial.
    Fauvel C; Liu Y; Correa-Jaque P; Kanwar MK; Vizza CD; Lin S; Benza RL
    Chest; 2023 Dec; 164(6):1518-1530. PubMed ID: 37356711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mortality in Pulmonary Arterial Hypertension in the Modern Era: Early Insights From the Pulmonary Hypertension Association Registry.
    Chang KY; Duval S; Badesch DB; Bull TM; Chakinala MM; De Marco T; Frantz RP; Hemnes A; Mathai SC; Rosenzweig EB; Ryan JJ; Thenappan T;
    J Am Heart Assoc; 2022 May; 11(9):e024969. PubMed ID: 35475351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of selective serotonin reuptake inhibitors and outcomes in pulmonary arterial hypertension.
    Sadoughi A; Roberts KE; Preston IR; Lai GP; McCollister DH; Farber HW; Hill NS
    Chest; 2013 Aug; 144(2):531-541. PubMed ID: 23558791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comorbid conditions and outcomes in patients with pulmonary arterial hypertension: a REVEAL registry analysis.
    Poms AD; Turner M; Farber HW; Meltzer LA; McGoon MD
    Chest; 2013 Jul; 144(1):169-176. PubMed ID: 23348820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.